- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07938073
Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma
To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Primary Objectives and Endpoints To evaluate the safety and efficacy of vorasidenib in participants with IDH2-mutated iCCA.
Primary endpoints for the study will be the evaluation of dose-limiting toxicities (DLTs) and landmark progression-free survival (PFS).
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Milind Javle, MD
- Numero di telefono: 713-792-5434
- Email: mjavle@mdanderson.org
Luoghi di studio
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
Contatto:
- Milind Javle, MD
- Numero di telefono: 713-792-5434
- Email: mjavle@mdanderson.org
-
Investigatore principale:
- Milind Javle, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Eligibility Criteria
-
Patients with diagnosis of unresectable or metastatic iCCA (confirmed by treating clinician) who have received at least one first-line standard of care systemic therapy for iCCA.
-
Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer
-
Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS).
-
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
-
Age ≥18 years.
-
ECOG performance status ≤2 (Karnofsky ≥60%,).
-
Patients must have adequate organ and marrow function as defined below:
- absolute neutrophil count ≥1,000/mcL
- platelets ≥75,000/mcL
- total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN
- Creatinine ≤ institutional ULN
-
For Participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable
-
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For Participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, Participants should be class 2B or better.
-
The effects of vorasidenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- History of hysterectomy or bilateral salpingo-oophorectomy.
- Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- History of bilateral tubal ligation or another surgical sterilization procedure.
-
Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
-
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and not donate sperm for the duration of study participation, and 4 months after completion of vorasidenib administration.
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
-
Prior treatment with an IDH inhibitor.
-
Participants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.
-
Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 2 with the exception of alopecia.
-
Participants who are receiving any other investigational agents.
-
Concomitant use of strong CYP3A4 inducers or inhibitors, or medications with potential for significant drug-drug interactions with vorasidenib as detailed in the prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf).
-
Participants with active brain metastases. The investigator(s) must state a medical or scientific reason if Participants who have brain metastases will be excluded from the study.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to [list out Agent(s)] or other agents used in study.
-
Examples of such agents or substances include those that interact through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-glycoprotein). Specifically excluded substances may be listed below and presented as an appendix. If appropriate, the following text concerning CYP450 interactions may be used or modified.
Note: This must account for all agents to be used in this study, including commercial agents. Please refer to the FDA product labels for all commercial agents and include information on prohibited concomitant medications in all applicable sections of the protocol.
-
Participants with uncontrolled intercurrent illness (Indicate clearly what type or extent)
-
Human immunodeficiency virus (HIV)-infected Participants are excluded, except those on effective ART with undetectable viral load, who are eligible.
-
Participants with psychiatric illness/social situations that would limit compliance with study requirements.
-
Pregnant women are excluded from this study because vorasidenib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorasidenib, breastfeeding should be discontinued if the mother is treated with vorasidenib. These potential risks may also apply to other agents used in this study.
-
The investigator(s) must state a medical or scientific reason if Participants who are cancer survivors will be excluded from the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Safety Run-In/Expansion
Treatment with Vorasidenib (PO) Q4W |
Give by po |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and adverse events (AEs
Lasso di tempo: Through study completion; an average of 1 year.
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0 |
Through study completion; an average of 1 year.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Milind Javle, MD, UT MD Anderson Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026-1152
- NCI-2026-08423 (Altro identificatore: NCI-CTRP Clinical Registry)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .